Completed PHASE1 INTERVENTIONAL 2-arm NCT01764594

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

A Multicenter, Investigator- and Subject-Blind, Randomized, Placebo-Controlled, Parallel-Group, Repeat-Dose Study to Evaluate the Effect of CDP7657 in Subjects With Active Systemic Lupus Erythematosus

Sponsor: Biogen

Conditions Autoimmune Diseases Connective Tissue Disease Immune System Diseases Lupus Erythematosus, Systemic Skin and Connective Tissue Diseases

Interventions CDP7657 Placebo

Updated 6 times since 2017 Last updated: Jul 14, 2015 Started: Jan 31, 2013 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Autoimmune Diseases and Connective Tissue Disease and is currently completed. Biogen leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Brussels, Belgium , Bucharest, Romania , Cluj-Napoca, Romania , Erlangen, Germany , Frankfurt, Germany , Greifswald, Germany , Hanover, Germany , Hospitalet Del Llobregat, Spain , Kiel, Germany and 9 more locations